As Moderna begins a late-stage trial of its vaccine, chief medical officer Tal Zaks sold almost all his shares in the company, according to a report filed to the US Securities and Exchange Commission, raising concerns about his trust in the vaccine.
As Moderna begins a late-stage trial of its vaccine, chief medical officer Tal Zaks sold almost all his shares in the company, according to a report filed to the US Securities and Exchange Commission, raising concerns about his trust in the vaccine.
